Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

In a USC Keck School of Medicine press release, senior author Susanne Hempel, PhD, said, "The main message is, if your doctor ...

Numerous treatment options for COVID-19 have been approved by the U.S. Food and Drug Administration over the last four years, ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

Credit: testing/Shutterstock. Organon has announced the acquisition of the US regulatory and commercial rights for intravenous infusion of the Actemra biosimilar, Tofidence, from Biogen. The move is ...

arthritis drug Actemra. Biogen (NASDAQ:BIIB), which obtained regulatory and commercial rights to Tofidence from the Chinese biotech Bio-Thera Solutions in 2021, launched the monoclonal antibody ...

Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar developed by Biogen (NASDAQ:BIIB) as an intravenous therapy targeting Roche’s ...

Roche’s Actemra may help fight pandemic after all with phase 3 trial results showing it cut the chances of COVID-19 patients, mainly from higher risk minority ethnic backgrounds with pneumonia ...

As with other drugs, Remicade (infliximab) can cause side effects, such as infusion reactions. If you are not able to tolerate side effects of Remicade, talk with your doctor or pharmacist ...

Key drugs in other therapeutic areas include Hemlibra, a bispecific antibody created by Chugai that has changed the treatment landscape for hemophilia A, and Actemra, an IL-6 inhibitor for ...

Elevated concentrations of interleukin-6 have been demonstrated to be an important key factor in COVID-19 host immune impairment. It represents an important prognostic factor of harm associated with ...